Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 193

1.

Molecular studies of the Oka varicella vaccine.

Quinlivan M, Breuer J, Schmid DS.

Expert Rev Vaccines. 2011 Sep;10(9):1321-36. doi: 10.1586/erv.11.93. Review.

PMID:
21919621
2.
3.
4.

Clinical and molecular aspects of the live attenuated Oka varicella vaccine.

Quinlivan M, Breuer J.

Rev Med Virol. 2014 Jul;24(4):254-73. doi: 10.1002/rmv.1789. Epub 2014 Mar 29. Review.

PMID:
24687808
5.

Molecular studies of Varicella zoster virus.

Quinlivan M, Breuer J.

Rev Med Virol. 2006 Jul-Aug;16(4):225-50. Review.

PMID:
16791838
6.

Analysis of varicella zoster virus attenuation by evaluation of chimeric parent Oka/vaccine Oka recombinant viruses in skin xenografts in the SCIDhu mouse model.

Zerboni L, Hinchliffe S, Sommer MH, Ito H, Besser J, Stamatis S, Cheng J, Distefano D, Kraiouchkine N, Shaw A, Arvin AM.

Virology. 2005 Feb 5;332(1):337-46.

7.
8.

Investigation of varicella-zoster virus neurotropism and neurovirulence using SCID mouse-human DRG xenografts.

Zerboni L, Arvin A.

J Neurovirol. 2011 Dec;17(6):570-7. doi: 10.1007/s13365-011-0066-x. Epub 2011 Dec 8. Review.

PMID:
22161683
9.

Molecular and therapeutic aspects of varicella-zoster virus infection.

Quinlivan M, Breuer J.

Expert Rev Mol Med. 2005 Aug 10;7(15):1-24. Review.

PMID:
16098235
10.

Varicella-zoster virus.

Arvin AM.

Clin Microbiol Rev. 1996 Jul;9(3):361-81. Review.

11.

Varicella-zoster virus neurotropism in SCID mouse-human dorsal root ganglia xenografts.

Zerboni L, Reichelt M, Arvin A.

Curr Top Microbiol Immunol. 2010;342:255-76. doi: 10.1007/82_2009_8. Review.

PMID:
20225014
12.

Varicella zoster virus vaccines: potential complications and possible improvements.

Silver B, Zhu H.

Virol Sin. 2014 Oct;29(5):265-73. doi: 10.1007/s12250-014-3516-9. Epub 2014 Oct 24. Review.

PMID:
25358998
13.

[Varicella-zoster virus (VZV)].

Kanai K, Yamada S, Inoue N.

Uirusu. 2010 Dec;60(2):197-207. Review. Japanese.

14.

Varicella-zoster virus infection of human dorsal root ganglia in vivo.

Zerboni L, Ku CC, Jones CD, Zehnder JL, Arvin AM.

Proc Natl Acad Sci U S A. 2005 May 3;102(18):6490-5. Epub 2005 Apr 25.

15.

The current status of live attenuated varicella vaccine.

Gershon AA.

Arch Virol Suppl. 2001;(17):1-6. Review.

PMID:
11339539
16.
17.

Emerging drugs for varicella-zoster virus infections.

Andrei G, Snoeck R.

Expert Opin Emerg Drugs. 2011 Sep;16(3):507-35. doi: 10.1517/14728214.2011.591786. Epub 2011 Jun 24. Review.

PMID:
21699441
18.

Varicella-zoster virus T cell tropism and the pathogenesis of skin infection.

Arvin AM, Moffat JF, Sommer M, Oliver S, Che X, Vleck S, Zerboni L, Ku CC.

Curr Top Microbiol Immunol. 2010;342:189-209. doi: 10.1007/82_2010_29. Review.

19.

Identification of an important immunological difference between virulent varicella-zoster virus and its avirulent vaccine: viral disruption of dendritic cell instruction.

Gutzeit C, Raftery MJ, Peiser M, Tischer KB, Ulrich M, Eberhardt M, Stockfleth E, Giese T, Sauerbrei A, Morita CT, Schönrich G.

J Immunol. 2010 Jul 1;185(1):488-97. doi: 10.4049/jimmunol.0902817. Epub 2010 Jun 4.

20.

The safety profile of varicella vaccine: a 10-year review.

Galea SA, Sweet A, Beninger P, Steinberg SP, Larussa PS, Gershon AA, Sharrar RG.

J Infect Dis. 2008 Mar 1;197 Suppl 2:S165-9. doi: 10.1086/522125. Review.

PMID:
18419392

Supplemental Content

Support Center